Bill
HR 3288
The Access to Prescription Digital Therapeutics Act mandates insurance coverage for digital therapeutics, improving access for patients and training for healthcare providers.
The Access to Prescription Digital Therapeutics Act of 2025 aims to enhance the accessibility and integration of prescription digital therapeutics (PDTs) into the healthcare system. This legislation seeks to ensure that patients can benefit from innovative digital health solutions that are prescribed by healthcare providers and covered by insurance plans.
The bill includes several significant provisions designed to facilitate the use of PDTs:
Definition of Digital Therapeutics: The bill establishes a clear definition of prescription digital therapeutics, distinguishing them from general wellness apps and ensuring they meet specific clinical standards.
Insurance Coverage: It mandates that health insurance plans cover prescribed digital therapeutics, similar to traditional medications, thereby reducing financial barriers for patients.
Provider Training and Education: The bill calls for the development of training programs for healthcare providers to ensure they are equipped to prescribe and integrate digital therapeutics into patient care effectively.
Data Privacy and Security: Provisions are included to protect patient data and ensure that digital therapeutics comply with existing privacy laws, such as HIPAA.
Evaluation and Reporting: The bill requires ongoing evaluation of the effectiveness of PDTs, including patient outcomes and cost-effectiveness, to inform future healthcare policies.
Patients: Individuals with chronic conditions or mental health issues who may benefit from digital therapeutics will have improved access to these innovative treatments.
Healthcare Providers: Physicians and other healthcare professionals will receive training and resources to incorporate digital therapeutics into their practice.
Insurance Companies: Health insurers will need to adapt their coverage policies to include prescription digital therapeutics, potentially impacting their cost structures.
Technology Developers: Companies that develop digital therapeutics will be encouraged to create products that meet the standards set forth in the legislation.
Introduced Date: The bill was introduced on May 08, 2025.
Current Status: As of the introduction date, HR 3288 has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means for further consideration.
Companion Bill: There is a related companion bill, S 1702, which is being considered in the Senate.
HR 3288 represents a significant step towards integrating digital health solutions into mainstream healthcare. By ensuring coverage and establishing standards for prescription digital therapeutics, the bill aims to improve patient outcomes and expand access to innovative treatments. As it moves through the legislative process, stakeholders across the healthcare spectrum will be closely monitoring its developments.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
